expect market growth pain brain driven therapi
attend north american neuromodul societi nan confer
gave investor updat market busi note market grow
expect compound-annual-growth-rate consist
comment low-teen growth continu view market healthi
under-penetr pain brain expect grow market
area context neuromodul revenu forecast
growth rate market rate confid market
growth underpin improv therapi low therapy/awar
creat opportun addit clinic data expand market rep
turnov issu continu build sale forc stage
estim patient implant annual versu get back
surgeri everi year mani sub-optim outcom see opioid crisi
tailwind patient look option pain relief
analysi ub evid lab survey data posit
remind launch analyz data ub evid
lab spine neuromodul survey view posit
neuromodul one compon acceler organ growth updat
nan increment revolutionari
view market continu move toward combin therapi
well posit shift wavewrit first fda approv system
combin therapi simultan provid paresthesia sub-percept therapi
simplifi deliveri person therapi autom patient feedback
also cosman rf ablat system pain reliabl gener broad
rang upstream applic signific synergi
valuat near high still vaunt growth multipl
multipl near recent high growth see upsid
share dd ep growth multipl expans top tier top line perform
trade data key metric
compani account thomson reuter ub estim ub adjust ep state goodwill-rel charg adjust abnorm econom item analyst
judgement valuat base averag share price year base share price jan estimate
report prepar ub secur llc analyst certif requir disclosur begin
page ub seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid
report singl factor make invest decis
ub research thesi map guid think report
 sustain market growth hsd rang
ye perhap dd potenti growth medsurg structur heart layer
growth new acquisit under-appreci guidanc ex-btg call
oper compound-annual-growth-rate think near high end con
ye margin improv dramat past year increas growth
shift mix institut cost cut measur margin still well comp like
expect grow om near middl bracket line con
 structur heart reach intervent cardiolog revenu
biggest growth driver growth trend watchman devic
strong penetr remain low acur valv seen increas uptak next gen
valv addit lotu help push eu/row market share
given strong underli trend rich organ pipelin addit nearli dozen technolog
tuck in posit deliv top-tier growth larg cap med-tech next three year
stock trade near high think multipl headroom given higher peer
valuat expect continu revenu surpris
detail analysi pipelin acquisit point potenti upsid sell-sid
revenu estim math sell-sid number account recent beat
trend-line acceler rich pipelin acquir product execut
date analysi peer margin program give us confid reach
margin time physician check suggest continu strong growth watchman
achiev market share tavr time
consensu long sell side estim call revenu growth mid-teen
earn growth next two year in-lin earn forecast revenu
growth consensu think out-performance drive re-rat
upsid downsid
compani descript boston scientif corpor global develop manufactur market medic devic
use broad rang intervent medic specialti compani
good year growth pain market driven
wavewrit abil simultan provid paresthesia sub-
percept therapi combin system includ infinion cx lead
allow easier target multipl mechan action pain area
time platform give patient option well includ
contact lead paddl mri compat non-recharg combin
clinic data foundat built proco random clinic
trial rct help support hypothesi outcom optim
provid option correct therapi dose look forward also
run combo rct demonstr valu multipl modal
combin mechan use spectra wavewrit read
acceler rct evalu safeti effect high-rat
meet shown data relief registri commerci
avail system show annual explant rate due inadequ
pain relief lower industri averag subject
registri report improv pain therapi three year
wavewrit real world outcom highlight averag
pain reduct rate respond rate pain relief three month
patient report minim pain patient pain free
db highlight vercis system approv
look expand sale us launch vercis pc gevia
direct system cartesia lead look forward run
clinic research studi drive adopt therapi expans includ
db registri intrepid rct double-blind sham control trial
vercis evalu util visual guid xt also
direct db trial evalu cartesia direct lead clover evalu
extern object measur close loop program
upsid downsid
upsid upsid case assum xfx growth
driven broad base product driver includ sever key new product
upsid deal predic stabl global market price trend
upsid case grow ebit margin
higher growth given modest line leverag forecast mid teen ep
growth period
base base case assum xfx growth driven
broad base product driver includ sever key new product
predic stabl global market price trend anticip
grow ebit margin digest deal invest
numer growth opportun given modest line leverag
forecast low teen ep growth period
downsid downsid case assum xfx growth
new product growth drag competit key area like
stent tough comp medsurg scenario would includ
modest soften global market price trend condit
anticip grow ebit margin digest deal
invest numer growth opportun given modest line
leverag forecast ldd ep growth period
global develop
manufactur market medic devic
use broad rang intervent medic specialti
compani three busi segment cardiovascular
sale rhythm manag medsurg
headquart marlborough
encourag sector fundament includ
renaiss big new product driver push innovation-
led growth drumbeat steadi volum increas
popul age emerg market
earli inning util time med-tech
risk rel contain price trend larg
stabl low cost implant find littl traction area
physician prefer
also view
favour polit part solut term
abil improv healthcar outcom lower cost
exposur growth market
cardio
increas breadth diversif invest
urolog endoscopi give leverag growth area
revenu region
revenu product segment
profit tax
profit tax
equival
invest asset
trade payabl st liabil
net incom pref div
net chang work capit
chang debt pref share
flow inc/ dec cash
balanc sheet inc/ dec cash
compani account ub estim ub metric use report figur adjust ub ep ub dilut calcul use ub net incom ad back depreci
buy minor
revenu divis us
rhythm neuro
ebit ub divis us
compani account ub estim ub metric use report figur adjust ub analyst
valuat method risk statement
price target base ep risk price target
includ slowdown core cardio neuro urolog end market increas
competit establish larg cap compani competit entrant
differenti technolog delay key product approv reject
regulatori bodi inabl deliv hsd top line growth meet consensu
expect top line miss guidanc consensu bottom line
delay lotu approv watchman growth slow expect
